Printer Friendly

FDA CLEARS LASER FOR TREATMENT OF UROLOGIC DISORDERS

 FDA CLEARS LASER FOR TREATMENT OF UROLOGIC DISORDERS
 PALO ALTO, Calif., May 13 /PRNewswire/ -- Coherent Inc.


(NASDAQ: COHR)(Palo Alto) announced today that they are the first company to receive clearance from the Food and Drug Adminstration (FDA) for use of its VersaPulse(TM) holmium lasers in urology. The holmium laser uses miniature fibers which allow surgeons to convert major surgery to minimally invasive procedures, thus allowing shorter hospital stays and faster recovery.
 The new laser procedures include the treatment of bladder tumors, urethral and ureteral strictures, condylomas, and lesions of the external genitalia, and bladder neck obstructions.
 Ted Belleza, director of marketing at Coherent, stated "Extensive clinical studies during the past two years have demonstrated the effectiveness of the new lasers in ablation, vaporization, incision, excision and coagulation of soft tissue encountered during urologic surgery."
 Two principal investigators conducted the pre-clinical studies that formed the basis of the FDA applications by Coherent: Douglas Johnson, M.D., professor of urology at the University of Texas M.D. Anderson Cancer Center, and George Fournier, M.D., assistant professor of medicine at the University of California in San Francisco. Johnson's work is summarized in a technical report to be presented at the conference of the American Society for Laser Medicine and Surgery which will be held in Orlando, Fla. next week.
 The VersaPulse holmium laser has truly become a multi-purpose, multi-specialty surgical tool. In 1990, the VersaPulse laser was cleared by the FDA for arthroscopic surgery in the knee, shoulder and other joints. Clearance for its use in open and endoscopic general surgery was issued in early 1991. Last September, VersaPulse was cleared for use in the treatment of lower-back disorders involving herniated disks. Other surgical specialties under active consideration include the use of VersaPulse in endoscopic sinus surgery and gynecology.
 Coherent Inc. is a worldwide leader in the development, manufacture and marketing of lasers and laser systems for medicine, science and industry.
 -0- 5/13/92
 /CONTACT: Edwina DeRousse of Coherent, 415-852-3636/
 (COHR) CO: Coherent Inc. ST: California IN: MTC SU:


MM -- SJ004 -- 9782 05/13/92 14:44 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:349
Previous Article:CRAY RESEARCH ANNOUNCES NET EARNINGS EXPECTATIONS
Next Article:COLUMBIA GAS TRANSMISSION CORPORATION GRANTED ADDITIONAL TIME TO FILE BANKRUPTCY REORGANIZATION PLAN
Topics:


Related Articles
SUMMIT TECHNOLOGY COMPLETES CLINICAL REQUIREMENTS FOR FDA PHASE III PHOTOREFRACTIVE KERATECTOMY (PRK) U.S. CLINICAL TRIALS
FDA ACCEPTS SUMMIT'S APPLICATION FOR APPROVAL TO COMMERCIALLY MARKET EXCIMER LASER SYSTEM FOR THERAPEUTIC APPLICATIONS
SUMMIT TECHNOLOGY RECEIVES IDE FROM FDA FOR TREATMENT OF ASTIGMATISM WITH HOLMIUM LASER SYSTEM
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
COHERENT TO BEGIN CLINICAL TRIALS ON LASER LITHOTRIPSY
SUMMIT RECEIVES FDA CLEARANCE TO SELL OMNIMED HOLMIUM LASER SYSTEM IN THE UNITED STATES
LASER CLEARED FOR ENDONASAL PROCEDURES
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
Spectranetics Expands Lead Removal Trial To Include ICDS; Expansion Follows FDA Okay Of Larger Laser Sheath

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters